VivoSeq
Gastroenterology

Alcoholic Liver Disease

6

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Alcoholic Liver Disease is an early-stage landscape with 6 programs across 3 companies. The most active players are AstraZeneca, Johnson & Johnson, Bayer. 1 therapy is approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 1Bayer logo

Bayer

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

86%

Small molecule

6 of 7 classified programs — the dominant modality here.

14%ALL OTHERSMonoclonal antibody114%

Small molecule leads; the ring shows all 7 classified programs, each share of the total. Modality classified for 100% of 7 pipeline programs.

Analysis

Trial Status

5

clinical trials

Completed3 · 60%
Not yet recruiting1 · 20%
Active, not recruiting1 · 20%

Clinical Trials

Trial Activity

Herbal Supplements for Improvement of Liver Function in Participants With Alcoholic Liver Disease
Not yet recruiting·CComposite Interceptive Med Science·N/A·NCT03503708·40 enrolled
Effects of SAMe in Patients With Alcoholic Liver Disease
Completed·UUniversity of California, Davis·Phase 3·NCT00573313·94 enrolled
Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease
Completed·—·Phase 4·NCT01501162·130 enrolled
Alcoholic Liver Disease and the Gut Microbiome
Active, not recruiting·UUniversity of California, Los Angeles·N/A·NCT05007470·80 enrolled
Baclofen in the Treatment of Alcohol Dependence With or Without Alcoholic Liver Disease
Completed·SSouth West Sydney Local Health District·Phase 3·NCT01711125·104 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)